Trovagene (TROV) Says Phase 1 Safety Study Supports Planned Development of PCM-075 in AML
Tweet Send to a Friend
Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced summary data from a phase 1 safety study conducted ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
